In this Vector report, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center reveal how the protein, BCL11A, controls the switch in the body’s production of fetal hemoglobin to adult hemoglobin.
News
Displaying 61-66 of 66 results matching:
Dana-Farber/Boston Children's is the only pediatric stem cell transplant center in the U.S. to exceed expected outcomes for allogeneic transplant patients in 2017.
As reported in Answers, researchers at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center have found that CDK12 inhibitors pack a particularly lethal punch to Ewing sarcoma, a rare cancer typically affecting children and young adults.
Alessandra Biffi, MD, led a study that shows the efficacy of a new gene therapy transplantation technique that could have future applications for treating neurodegenerative diseases.
David Williams, MD, discusses Dana-Farber/Boston Children's new gene therapy clinical trial for sickle cell disease in a live webchat.
Two Dana-Farber/Boston Children's Cancer and Blood Disorders Center faculty members, Scott Allen Armstrong, MD, PhD, and Scott Pomeroy, MD, PhD, have been elected to the National Academy of Medicine (NAM).